Evaluating the RESET care program:Advancing towards scalable and effective healthcare solutions for metabolic dysfunctionassociated liver disease  

作　　者：Mariana M Ramírez-Mejía Froylan D Martínez-Sánchez Jacqueline Córdova-Gallardo Nahum Méndez-Sánchez 

机构地区：[1]Plan of Combined Studies in Medicine,Faculty of Medicine,National Autonomous University of Mexico,Mexico City 04360,Mexico [2]Liver Research Unit,Medica Sur Clinic and Foundation,Mexico City 14050,Mexico [3]Department of Internal Medicine,Hospital General“Dr.Manuel Gea González”,Mexico City 4800,Mexico [4]Department of Hepatology,Hospital General“Dr.Manuel Gea González”,Mexico City 4800,Mexico [5]Faculty of Medicine,National Autonomous University of Mexico,Mexico City 04360,Mexico

出　　处：《World Journal of Hepatology》2025年第4期160-166,共7页世界肝病学杂志(英文)

摘　　要：In this article,we discuss the recently published article by Soni et al.This study explores the effectiveness of a comprehensive digital health program,RESET care,which integrates personalized dietary plans,structured exercise,and cognitive behavioral therapy delivered through a mobile app equipped with Internet of Things devices such as body composition analyzers and smartwatches.Metabolic dysfunction-associated liver disease(MASLD),a global health burden affecting approximately 25%of the population,demands sustainable lifestyle modifications as its primary management strategy.The study reports that 100%of participants in the comprehensive intervention group(diet+exercise+cognitive behavioral therapy)achieved a weight reduction≥7%(6.99±2.98 kg,7.00%±3.39%;P=0.002),a clinically significant threshold for MASLD improvement.In addition,participants showed a mean weight reduction of 6.99 kg(101.10±17.85 vs 94.11±17.38,P<0.001)and a body mass index reduction of 2.18 kg/m²(32.90±3.02 vs 30.72±3.41,P<0.001).These results underscore the potential of digital health platforms to provide scalable,evidence-based solutions for the treatment of MASLD.While these results highlight the potential of digital platforms in the scalable and personalized management of MASLD,the small study sample size and short duration of follow-up limit the generalizability of the results.Future large-scale,long-term trials are needed to confirm sustained benefits,cost-effectiveness,and broader applicability.This letter contextualizes the study within the evolving landscape of MASLD management and emphasizes the clinical implications of integrating digital technologies into standard care.

关 键 词：Steatotic liver disease Digital health interventions Diet and exercise regimens Lifestyle modifications Metabolic dysfunction-associated liver disease 

分 类 号：R575[医药卫生—消化系统]